Microbiologics Introduces SARS-CoV-2 Synthetic RNA for COVID-19 Research

Microbiologics, Inc. (Saint Cloud, MN, USA) has prepared synthetic RNA for SARS-CoV-2 to assist in the efforts to monitor the spread of COVID-19.

Microbiologics, a biological products and services provider, partners with healthcare and life science laboratories, manufacturers and suppliers across the world to co-create and provide biological control materials, assay services and consulting for microbiology, molecular diagnostics and virology.


The SARS-CoV-2 material is a 1044 nucleotide RNA specific for the SARS-CoV-2 N (nucleocapsid) gene. It contains all three markers (N1, N2 and N3) detected by the CDC Real-Time RT PCR Panel for Detection of 2019 Novel Coronavirus. The RNA material assists in the development of diagnostic assays and the evaluation of the performance of nucleic acid tests for determination of the presence of SARS-COV-2.

The SARS-CoV-2 RNA is available in two different concentrations: 1 x 106 and 1 x 109 genome copies per tube. An IVD version of the product will be added to the Helix EliteTM line from Microbiologics and will be available in the coming weeks.

“We are engaged with our partners and researchers to offer Microbiologics’ virology and molecular biology capabilities to accelerate diagnostics and therapeutic research,” said Brian Beck, Microbiologics’ VP of R&D. “This new RNA material from Microbiologics mimics the viral nucleic acid and provides the exact targets specified by the CDC.”

“In order to effectively respond to the COVID-19 outbreak, scientists need to have confidence in their diagnostic tools to provide rapid, accurate results,” added Beck. “This SARS-CoV-2 material is a critical step forward in our global response against this new strain of coronavirus.”

Related Links:
Microbiologics, Inc.